Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate

Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19318598

DOI
10.1345/aph.1L555

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Alendronate /administration & dosage /adverse effects; Cohort Studies; Diphosphonates /administration & dosage /adverse effects; Drug Administration Schedule; Etidronic Acid /administration & dosage /adverse effects /analogues & derivatives; Female; Gastrointestinal Diseases /chemically induced /epidemiology /physiopathology; Humans; Middle Aged; Osteoporosis /drug therapy /physiopathology; Retrospective Studies; Risedronate Sodium; Risk Factors

AccessionNumber
22009101974

Date bibliographic record published
10/03/2010